SELLAS Life Sciences Group, Inc. (SLS) stock
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.15+11.68 (+156.36%)
Close on Nov 17, 2026Market cap $3.87BP/E –Yield –
SELLAS Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
SELLAS Life Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.35M, up 28.2% year over year. For fiscal 2025 it was $16.02M, down 16.1% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $27.67M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.02M | -16.1% |
| FY2024 | Dec 31, 2024 | $19.10M | -20.5% |
| FY2023 | Dec 31, 2023 | $24.01M | +18.4% |
| FY2022 | Dec 31, 2022 | $20.27M | +29.3% |
| FY2021 | Dec 31, 2021 | $15.67M | +68.9% |
| FY2020 | Dec 31, 2020 | $9.28M | +27.4% |
| FY2019 | Dec 31, 2019 | $7.29M | -16.9% |
| FY2018 | Dec 31, 2018 | $8.77M | +44.5% |
| FY2017 | Dec 31, 2017 | $6.07M | -46.8% |
| FY2016 | Dec 31, 2016 | $11.40M | -51.7% |
| FY2015 | Dec 31, 2015 | $23.61M | -14.7% |
| FY2014 | Dec 31, 2014 | $27.67M | +35.5% |
| FY2013 | Dec 31, 2013 | $20.42M | +39.8% |
| FY2012 | Dec 31, 2012 | $14.61M | +279.5% |
| FY2011 | Dec 31, 2011 | $3.85M | -51.1% |
| FY2010 | Dec 31, 2010 | $7.87M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.27M | +62.0% |
| Q1 FY2026 | Mar 31, 2026 | $5.13M | +60.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.73M | +6.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.22M | -3.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.87M | -25.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.21M | -37.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.44M | -12.9% |
| Q3 FY2024 | Sep 30, 2024 | $4.36M | -25.0% |
| Q2 FY2024 | Jun 30, 2024 | $5.19M | -12.4% |
| Q1 FY2024 | Mar 31, 2024 | $5.11M | -28.8% |
| Q4 FY2023 | Dec 31, 2023 | $5.10M | -12.8% |
| Q3 FY2023 | Sep 30, 2023 | $5.81M | +35.8% |
| Q2 FY2023 | Jun 30, 2023 | $5.92M | +7.1% |
| Q1 FY2023 | Mar 31, 2023 | $7.17M | +55.6% |
| Q4 FY2022 | Dec 31, 2022 | $5.85M | +72.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.28M | -5.7% |
| Q2 FY2022 | Jun 30, 2022 | $5.53M | +60.0% |
| Q1 FY2022 | Mar 31, 2022 | $4.61M | +7.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.39M | +22.4% |
| Q3 FY2021 | Sep 30, 2021 | $4.54M | +91.8% |
| Q2 FY2021 | Jun 30, 2021 | $3.46M | +51.6% |
| Q1 FY2021 | Mar 31, 2021 | $4.28M | +129.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.77M | +23.4% |
| Q3 FY2020 | Sep 30, 2020 | $2.37M | +31.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.28M | +65.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.86M | +0.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.25M | -38.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.80M | +4.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.38M | -13.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.86M | +3.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.65M | +269.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.72M | +61.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.59M | -12.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.80M | -17.4% |
| Q4 FY2017 | Dec 31, 2017 | $988.00K | -78.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.07M | -70.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.83M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.18M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.62M | – |
See a number that looks wrong?